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Abstract 
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease 
(CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully 
evaluated. Herein we describe three CD cases who presented with gastrointestinal 
bleeding and received infliximab treatment. In case 1, double-balloon endoscopy 
showed a large ulcer with several irregularly shaped ulcers in the terminal ileum; 8 weeks 
after infliximab administration, complete healing of all lesions was observed. In case 2, 
double-balloon endoscopy showed linear ulcers and mucosal edema in the jejunum and 
ileum; 5 weeks after infliximab administration, all lesions were decreased in size and 
were healed. In case 3, double-balloon endoscopy revealed ulcerations and stenosis in 
the terminal ileum; 12 weeks after infliximab administration, ulcer healing and an 
increased diameter of the ileal stenosis were observed. These three cases have been 
receiving ongoing infliximab maintenance therapy and are currently symptom-free. 
Infliximab thus appears to be useful for treatment of gastrointestinal bleeding in CD 
patients. 
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Introduction 
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. 
Although mild disease can be treated with 5-aminosalicylates (5-ASAs), many patients 
eventually require corticosteroids for symptom control [1]. Tumor necrosis factor α 
(TNF-α) is a proinflammatory cytokine that plays an important role in CD pathogenesis 
[2–4]. Infliximab, a chimeric monoclonal antibody directed against TNF-α that 
neutralizes its biological activity [5], was the first biological therapy to be approved for 
CD and has become an important tool in the treatment of this disease. 
Infliximab has been recommended by different organizations for induction therapy 
and maintenance therapy of CD. The definitive indications for induction therapy with 
infliximab are: (1) moderate to severe inflammatory CD with an inadequate response to 
conventional therapy (defined by severity of symptoms and/or lack of response to 
standard therapy such as corticosteroids, azathioprine, 6-mercaptopurine, and 
methotrexate); (2) fistulizing CD with draining cutaneous or perianal fistulas. 
The definitive indications for maintenance therapy with infliximab are: 
(1) inflammatory or fistulizing CD that responded to initial induction therapy with 
infliximab and failed maintenance therapy with one or more immunosuppressive agents; 
(2) corticosteroid-treated CD that failed an attempt at corticosteroid sparing with one or 
more immunosuppressive agents [6]. Other potential uses of infliximab in different CD 
settings are currently under investigation. We have used infliximab in CD patients 
previously controlled by immunosuppressive agents who presented with perirectal 
bleeding. Herein we report the effects of infliximab on gastrointestinal bleeding in CD. 
This is the first report of evaluation of small bowel CD lesions before and after 
administration of infliximab using double-balloon endoscopy. 
Case Reports 
Case 1 was an 18-year-old male who was admitted to our hospital after complaining of melena for 
1 day. He had a 2-year history of CD. His serum C-reactive protein (CRP) level was 2.7 mg. 
Colonoscopy showed a linear ulcer in the descending colon with no evidence of bleeding. A few 
aphthous ulcers were observed in the transverse colon and terminal ileum with no signs of bleeding. 
Double-balloon endoscopy revealed one large ulcer and several irregularly shaped ulcers in the terminal 
ileum (fig. 1a). The patient was given a single intravenous 5 mg/kg dose of infliximab. Eight weeks after 
infliximab administration, double-balloon endoscopy revealed a reduction in size and complete healing 
of the lesions (fig. 1b). The patient has been receiving infliximab maintenance therapy at a dose of 
5 mg/kg every 8 weeks. He is currently symptom-free with no evidence of disease relapse. 
Case 2 was a 21-year-old female who was admitted to our hospital after complaining of melena for 
2 days. She had a 5-year history of CD. Her serum CRP level was 4.6 mg/dl. Double-balloon endoscopy 
showed linear ulcers in the jejunum with ulcer scars. The ileum also showed ulcer scars with mucosal 
edema. The patient was given intravenous infliximab 5 mg/kg. Five weeks after infliximab 
administration, double-balloon endoscopy showed that all lesions were decreased in size and were 
healed. The patient has been receiving infliximab maintenance therapy every 8 weeks. She is currently 
symptom-free. 
Case 3 was a 31-year-old female who visited our hospital with mild abdominal pain without melena. 
On physical examination she was found to be anemic (hemoglobin level 5.9 g/dl) and her serum CRP 
was 1.0 mg/dl. The patient had a 2-year history of CD. Colonoscopy showed aphthous ulcers in the 
colon. Subsequently, double-balloon endoscopy revealed ulcerations and stenosis in the terminal ileum 
(fig. 2a). The patient was given infliximab 5 mg/kg. Twelve weeks after infliximab administration, 
double-balloon endoscopy showed ulcer healing and an increased diameter of the ileal stenosis (fig. 2b). 
The patient has been receiving infliximab maintenance therapy. She is currently symptom-free and her 
anemia is improving.  
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Discussion 
Acute lower gastrointestinal hemorrhage in an unusual complication of CD that occurs 
in 0.9–6% of cases [7–9]. Localization of the disease site remains a major challenge. 
Double-balloon endoscopy has been useful for identifying the bleeding site and also for 
excluding non-CD-related perirectal bleeding. Both medical and surgical modalities are 
used to manage lower gastrointestinal bleeding due to CD. Traditionally, medical 
treatment of CD primarily consisted of 5-ASAs and corticosteroids, with other, 
nonsurgical therapies including endoscopic treatment and interventional angiography. 
However, the outcomes or these therapies are not satisfactory, and 60–91% of cases 
require surgery [8]. Furthermore, up to 35% of medically treated patients experience 
recurrent bleeding episodes [7]. Although rebleeding is negligible in patients who 
undergo primary excisional surgery, such surgery is associated with various hazardous 
complications. 
The anti-TNF-α antibody infliximab has been shown to induce rapid mucosal healing 
[10, 11]. Infliximab treatment of severe, recurrent CD presenting as massive lower 
gastrointestinal bleeding has been shown to result in rapid mucosal healing and to 
prevent recurrent bleeding [12, 13], suggesting that infliximab may offer a viable 
treatment alternative to surgery for patients with acute massive or chronic refractory 
bleeding [14]. Furthermore, infliximab could potentially modify the expected time course 
of the disease in a relevant number of patients by stopping further development of, or 
causing regression of, stenotic lesions, thereby postponing or avoiding surgical 
interventions [15]. In our series, all three patients promptly responded to infliximab 
therapy, as their gastrointestinal bleeding stopped after a single dose and stenosis also 
improved. Furthermore, these patients have also received continual maintenance therapy 
with no evidence of disease relapse. It therefore seems feasible that infliximab may be 
useful in treating CD relapse characterized by gastrointestinal bleeding in patients who 
previously received other therapies. 
In conclusion, we have reported that all of our patients promptly responded to 
infliximab therapy, manifested as halting of gastrointestinal bleeding. This is the first 
report to show double-balloon endoscopic findings before and after administration of 
infliximab, which appears to be useful for stopping gastrointestinal bleeding and thereby 
preventing the need for surgery in CD patients. 
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Fig. 1. a Double-balloon endoscopy showed a large ulcer and several irregularly shaped ulcers in the 
terminal ileum. b Double-balloon endoscopy showed a reduction in size and complete healing of the 
lesions in the terminal ileum 8 weeks after infliximab treatment. 
 
 
 
Fig. 2. a Double-balloon endoscopy revealed ulcerations and stenosis in the terminal ileum. 
b Double-balloon endoscopy showed ulcer healing and an increased diameter of the ileal stenosis 12 
weeks after infliximab treatment. 
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